Swiss National Bank Sells 4,400 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Swiss National Bank reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,700 shares of the medical research company’s stock after selling 4,400 shares during the quarter. Swiss National Bank’s holdings in Bio-Rad Laboratories were worth $17,969,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Venturi Wealth Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after buying an additional 87 shares during the period. Asset Planning Inc purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth $33,000. UMB Bank n.a. lifted its holdings in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the period. Cape Investment Advisory Inc. purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth $38,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth $55,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Trading Up 1.2 %

BIO opened at $260.16 on Wednesday. The firm has a market cap of $7.29 billion, a price-to-earnings ratio of -4.00 and a beta of 0.98. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12 month low of $244.00 and a 12 month high of $387.99. The stock has a fifty day moving average price of $308.56 and a 200-day moving average price of $326.91.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.